Cardiol Therapeutics (CRDL) Operating Leases (2020 - 2026)

Cardiol Therapeutics has reported Operating Leases for 7 years, with the latest figure at $55868.8 in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 31.13% year-over-year to $55868.8; the trailing twelve-month figure through Mar 2026 stood at $55868.8 (down 31.13% YoY), and the FY2025 full-year result was $62512.7, down 30.43% from the prior year.
• Operating Leases for Q1 2026 stood at $55868.8, down from $62512.7 in the prior quarter.
• The five-year high for Operating Leases was $116447.4 in Q4 2023, with the low at $6723.1 in Q1 2023.
• Historically, Operating Leases has averaged $69858.1 across 5 years, with a median of $73952.2 in 2025.
• Annual changes were most pronounced in 2023 — Operating Leases sank 85.96% — and 2024, when it surged 1563.02%.
• Cardiol Therapeutics' Operating Leases stood at $16519.8 in 2022, then jumped by 604.89% to $116447.4 in 2023, then fell by 22.84% to $89855.5 in 2024, then plunged by 30.43% to $62512.7 in 2025, then dropped by 10.63% to $55868.8 in 2026.
• The last three Operating Leases figures came in at $55868.8 (Q1 2026), $62512.7 (Q4 2025), and $70682.7 (Q3 2025), per Business Quant data.